Clinical trials
Observational Cardiotoxicity trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Active, not recruiting | 5 |
| Recruiting | 4 |
| Enrolling by invitation | 2 |
| Terminated | 2 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Abramson Cancer Center at Penn Medicine | 8 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Connecticut Children's Medical Center | 1 |
| Daniel Rushing | 1 |
| George Washington University | 1 |
| Hari Narayan | 1 |
| Majd Makhoul | 1 |
| Mayo Clinic | 1 |
| Medical College of Wisconsin | 1 |
| Niti Dham | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiotoxicity | 30 |
| Breast Neoplasms | 11 |
| Heart Failure | 7 |
| Neoplasms | 6 |
| Cardiovascular Diseases | 4 |
| Lymphoma | 4 |
| Lung Neoplasms | 3 |
| Coronary Artery Disease | 2 |
| Drug-Related Side Effects and Adverse Reactions | 2 |
| Hypertension | 2 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.